Showing 9011-9020 of 9757 results for "".
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- NuFace Names New CEOhttps://practicaldermatology.com/news/nuface-names-new-ceo/2460504/Michael Larrain is the new Chief Executive Officer at NuFACE. Tera Peterson, former CEO, will remain at the company as Co-Founder, Chairman of the Board and Chief Creative Officer. Larrain was CEO at PCA Skin and held seve
- SoftWave Tissue Regeneration Technologies Takes On Cellulitehttps://practicaldermatology.com/news/softwave-tissue-regeneration-technologies-takes-on-cellulite/2460494/SoftWave Tissue Regeneration Technologies plans to start a 60-patient study to evaluate the safety and efficacy of the DermaGold device for the temporary improvement in the appearance of cellulite. The company has a pa
- Early Study Demonstrates Roflumilast cream Safe and Effective for Chronic Plaque Psoriasishttps://practicaldermatology.com/news/early-study-demonstrates-roflumilast-cream-safe-and-effective-for-chronic-plaque-psoriasis/2460493/Arcutis Biotherapeutics, Inc. shared positive results from a Phase 1/2a trial of its investigational drug topical roflumilast cream for the treatment of chronic plaque psoriasis that were published in the August issue of the Journal of Drugs in Dermatology. The results demonstrate that ARQ-151 (r
- George W. Mahaffey Named CEO of Mindera Corporationhttps://practicaldermatology.com/news/george-w-mahaffey-named-ceo-of-mindera-corporation/2460480/George W. Mahaffey is the new President and Chief Executive Officer of Mindera Corporation. He will also serve as a Director of the Company. Mindera has developed a novel platform to extract thousands of biomarkers from an individual patient via a dermal biomarker patch. Captured R
- Researchers Explore Nitric Oxide to Slow Progression of COVID-19https://practicaldermatology.com/news/industry-responds-to-covid-19-researchers-call-for-exploration-of-nitric-oxide-to-slow-progression-of-covid-19/2460477/George Washington University (GW) researchers urge renewed research of nitric oxide treatment as a potential tool to fight SARS-CoV-2, the coronavirus that causes COVID-19, in a review published in the journal Nitric Oxide. The authors suggest that if nitric oxide's efficacy is illustrat
- New Infographic Compares Rashes to COVID Toeshttps://practicaldermatology.com/news/new-infographic-compare-rashes-to-covid-toes/2460461/A new infographic from First Derm compares and contrasts rashes associated with COVID-19.
- ISD Survey: Climate Change Is A Real Threat to Skin Healthhttps://practicaldermatology.com/news/isd-survey-climate-change-is-a-real-threat-to-skin-health/2460451/The vast majority of dermatologists (95.6 percent) believe climate change is occurring and 88.6 percent indicated that climate change will impact the incidence of skin diseases in their areas, according to an online survey was conducted by the International Society of Dermatology's (ISD)
- Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumabhttps://practicaldermatology.com/news/bimekizumab-phase-3-data-show-superior-skin-clearance-in-moderate-to-severe-psoriasis/2460421/UCB shared first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns